Nothing Special   »   [go: up one dir, main page]

MA41090A - Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson - Google Patents

Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson

Info

Publication number
MA41090A
MA41090A MA041090A MA41090A MA41090A MA 41090 A MA41090 A MA 41090A MA 041090 A MA041090 A MA 041090A MA 41090 A MA41090 A MA 41090A MA 41090 A MA41090 A MA 41090A
Authority
MA
Morocco
Prior art keywords
adhd
parkinson
antagonist
dose
disease
Prior art date
Application number
MA041090A
Other languages
English (en)
Inventor
Johan Areberg
Nathalie Breysse
Gamini Chandrasena
Lone Frydelund Larsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA41090A publication Critical patent/MA41090A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MA041090A 2014-12-03 2015-11-30 Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson MA41090A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03

Publications (1)

Publication Number Publication Date
MA41090A true MA41090A (fr) 2017-10-10

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041090A MA41090A (fr) 2014-12-03 2015-11-30 Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson

Country Status (25)

Country Link
US (2) US20160158211A1 (fr)
EP (1) EP3226863A1 (fr)
JP (1) JP2017536400A (fr)
KR (1) KR20170090430A (fr)
CN (1) CN106999480A (fr)
AU (1) AU2015357197A1 (fr)
BR (1) BR112017011777A2 (fr)
CA (1) CA2966582A1 (fr)
CL (1) CL2017001407A1 (fr)
CO (1) CO2017004785A2 (fr)
CR (1) CR20170221A (fr)
DO (1) DOP2017000121A (fr)
EA (1) EA201790973A1 (fr)
EC (1) ECSP17030050A (fr)
IL (1) IL252355A0 (fr)
MA (1) MA41090A (fr)
MX (1) MX2017007027A (fr)
NI (1) NI201700066A (fr)
PE (1) PE20170926A1 (fr)
PH (1) PH12017500923A1 (fr)
SG (1) SG11201704370XA (fr)
SV (1) SV2017005441A (fr)
TN (1) TN2017000174A1 (fr)
TW (1) TW201632186A (fr)
WO (1) WO2016087429A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105721A1 (fr) 2018-07-05 2020-01-09 Incyte Corporation Derives de pyrazine fusionnes en tant qu'inhibiteurs d'a2a/a2b
KR20210114963A (ko) 2019-01-11 2021-09-24 오메로스 코포레이션 암을 치료하기 위한 방법 및 조성물
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629414T3 (es) * 2003-12-26 2017-08-09 Kyowa Hakko Kirin Co., Ltd. Derivados de tiazol
WO2010010908A1 (fr) * 2008-07-23 2010-01-28 協和発酵キリン株式会社 Agent thérapeutique antimigraineux
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів

Also Published As

Publication number Publication date
PH12017500923A1 (en) 2017-11-20
NI201700066A (es) 2018-01-04
EP3226863A1 (fr) 2017-10-11
EA201790973A1 (ru) 2017-10-31
DOP2017000121A (es) 2017-07-15
JP2017536400A (ja) 2017-12-07
AU2015357197A1 (en) 2017-05-25
CO2017004785A2 (es) 2017-08-31
SG11201704370XA (en) 2017-06-29
MX2017007027A (es) 2017-08-24
CA2966582A1 (fr) 2016-06-09
CR20170221A (es) 2017-10-05
TW201632186A (zh) 2016-09-16
US20160158211A1 (en) 2016-06-09
ECSP17030050A (es) 2017-08-31
PE20170926A1 (es) 2017-07-13
WO2016087429A1 (fr) 2016-06-09
CN106999480A (zh) 2017-08-01
IL252355A0 (en) 2017-07-31
SV2017005441A (es) 2017-08-25
CL2017001407A1 (es) 2018-01-05
US20180125835A1 (en) 2018-05-10
KR20170090430A (ko) 2017-08-07
BR112017011777A2 (pt) 2018-02-20
TN2017000174A1 (en) 2018-10-19

Similar Documents

Publication Publication Date Title
IL246917A0 (en) Biomarker and early diagnosis methods for Alzheimer's disease
EP3337465A4 (fr) Compositions et méthodes d'utilisation en association destinées au traitement et au diagnostic de maladies auto-immunes
IL247085B (en) Methods for treating Alzheimer's disease
ZA201901826B (en) Cell suspension for use in the treatment of lower extremity peripheral artery disease
IL246999B (en) Methods for treating Alzheimer's disease
MA41115A (fr) Procédé de traitement de la maladie d'alzheimer
GB201504432D0 (en) Materials and methods for diagnosis and treatment of alzheimers disease
PT3405215T (pt) Métodos para o tratamento da doença de danon e outros transtornos da autofagia
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
MA41090A (fr) Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
FR3020951B1 (fr) Association d'un tetrapeptide et d'un glyceryl ester pour le traitement de l'alopecie androgenique.
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
HK1243709A1 (zh) 可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
PL3449009T3 (pl) Biomarkery mikroRNA we krwi do diagnozowania choroby Alzheimera
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
FR3031112B1 (fr) Construction d'adn pour le traitement de pathologies oculaires
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
ZA201808361B (en) Benzoxazine or quinazoline derivatives for use in the treatment of alzheimer¿s disease
PL3352777T3 (pl) Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona
MA40065A (fr) N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
FR3016881B1 (fr) Traitement des degenerescences et des lesions photo-induites de la retine
MA45177A (fr) Traitement de la maladie de parkinson
AU2016902338A0 (en) Agents and methods for the diagnosis and treatment of disease